Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001104659-25-035118
Filing Date
2025-04-15
Accepted
2025-04-15 16:05:50
Documents
22
Period of Report
2025-06-20

Document Format Files

Seq Description Document Type Size
1 PRE 14A tm252402-2_pre14aseq1.htm   iXBRL PRE 14A 983191
4 GRAPHIC bc_actualpaidvsnetloss-4c.jpg GRAPHIC 57727
5 GRAPHIC bc_actualpaidvstsr-4c.jpg GRAPHIC 54765
6 GRAPHIC lg_nextcure-4c.jpg GRAPHIC 17233
7 GRAPHIC pc_diver-4c.jpg GRAPHIC 26030
8 GRAPHIC px_nextcure2025pg01-bw.jpg GRAPHIC 263918
9 GRAPHIC px_nextcure2025pg02-bw.jpg GRAPHIC 190836
10 GRAPHIC tbl_board-4c.jpg GRAPHIC 129589
  Complete submission text file 0001104659-25-035118.txt   3483564

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA nxtc-20241231.xsd EX-101.SCH 9036
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE nxtc-20241231_lab.xml EX-101.LAB 33969
25 EXTRACTED XBRL INSTANCE DOCUMENT tm252402-2_pre14aseq1_htm.xml XML 129524
Mailing Address 9000 VIRGINIA MANOR ROAD, SUITE 200 BELTSVILLE MD 20705
Business Address 9000 VIRGINIA MANOR ROAD, SUITE 200 BELTSVILLE MD 20705 240-399-4900
NextCure, Inc. (Filer) CIK: 0001661059 (see all company filings)

EIN.: 475231247 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-38905 | Film No.: 25839524
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)